ProDa BioTech
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, ProDa BioTech sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
ProDa BioTech: 3 sponsored US clinical trials, 2 recruiting.
ProDa BioTech sponsors 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Pancreatic Cancer, with 1 trials.
Upper-quartile sponsor footprint
ProDa BioTech sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
NCT06460298
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06182072
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
NCT05085548
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
What is open in the ProDa BioTech pipeline
2 recruiting of 3 indexed (67% open).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Advanced Pancreatic Cancer (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
ProDa BioTech: open-pipeline peers nationwide
Peers matched on 3 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
ProDa BioTech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- Abbisko Therapeutics Co · 67% recruiting · 6 trials
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
Related
What to do with this ProDa BioTech page
3 registered trials is a research-attention snapshot, not an endorsement of ProDa BioTech or any single study.
- 2 of ProDa BioTech's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Pancreatic Cancer is the condition ProDa BioTech studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Pancreatic Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
ProDa BioTech pipeline card: 3 registered trials from official public datasets.Report a data error.